Exclusive Summary

• Differentiated Delivery Format: UB438 utilizes a unique Nasal Spray formulation, offering superior compliance for ALS patients (who often suffer from dysphagia) compared to oral or injectable competitors.
• De-risked Mechanism of Action: Built on the same proprietary ECIWEP platform as the lead asset (UBD001) which holds FDA Orphan Drug and Breakthrough Therapy designations, reducing biological risk via a validated neuro-repair mechanism.
• Manufacturing Scalability: As a "cell-free" protein therapy, it offers high batch-to-batch consistency and lower production costs compared to stem cell or exosome therapies, presenting a strong commercial barrier.

Asset Materials

Contact Us for Full Materials